TY - JOUR
T1 - A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer's disease
AU - Reddy, P. Hemachandra
AU - Tonk, Sahil
AU - Kumar, Subodh
AU - Vijayan, Murali
AU - Kandimalla, Ramesh
AU - Kuruva, Chandra Sekhar
AU - Reddy, Arubala P.
N1 - Funding Information:
Work presented in this article is supported by NIH grants – AG042178 and AG47812 and Garrison Family Foundation (to PHR). Present work is also supported by Alzheimer's Association New Investigator Research Grant 2016-NIRG-39787 and Center of Excellence For Translational Neuroscience and Therapeutics grant number PN-CTNT20115-AR (to APR).
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2017/2/19
Y1 - 2017/2/19
N2 - Currently, 5.4 million Americans suffer from AD, and these numbers are expected to increase up to 16 million by 2050. Despite tremendous research efforts, we still do not have drugs or agents that can delay, or prevent AD and its progression, and we still do not have early detectable biomarkers for AD. Multiple cellular changes have been implicated in AD, including synaptic damage, mitochondrial damage, production and accumulation of Aβ and phosphorylated tau, inflammatory response, deficits in neurotransmitters, deregulation of the cell cycle, and hormonal imbalance. Research into AD has revealed that miRNAs are involved in each of these cellular changes and interfere with gene regulation and translation. Recent discoveries in molecular biology have also revealed that microRNAs play a major role in post-translational regulation of gene expression. The purpose of this article is to review research that has assessed neuroprotective and neurodegenerative characteristics of microRNAs in brain samples from AD transgenic mouse models and patients with AD.
AB - Currently, 5.4 million Americans suffer from AD, and these numbers are expected to increase up to 16 million by 2050. Despite tremendous research efforts, we still do not have drugs or agents that can delay, or prevent AD and its progression, and we still do not have early detectable biomarkers for AD. Multiple cellular changes have been implicated in AD, including synaptic damage, mitochondrial damage, production and accumulation of Aβ and phosphorylated tau, inflammatory response, deficits in neurotransmitters, deregulation of the cell cycle, and hormonal imbalance. Research into AD has revealed that miRNAs are involved in each of these cellular changes and interfere with gene regulation and translation. Recent discoveries in molecular biology have also revealed that microRNAs play a major role in post-translational regulation of gene expression. The purpose of this article is to review research that has assessed neuroprotective and neurodegenerative characteristics of microRNAs in brain samples from AD transgenic mouse models and patients with AD.
KW - Alzheimer's disease
KW - Mitochondrial dysfunction
KW - Phosphorylated tau
KW - Synaptic damage
KW - microRNAs
UR - http://www.scopus.com/inward/record.url?scp=84992699734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992699734&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2016.08.067
DO - 10.1016/j.bbrc.2016.08.067
M3 - Review article
C2 - 27524239
AN - SCOPUS:84992699734
SN - 0006-291X
VL - 483
SP - 1156
EP - 1165
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 4
ER -